Plus Therapeutics, Inc. traded at $0.50 this Tuesday August 9th, decreasing $0.02 or 3.83 percent since the previous trading session. Looking back, over the last four weeks, Plus Therapeutics, Inc. lost 7.25 percent. Over the last 12 months, its price fell by 73.26 percent. Looking ahead, we forecast Plus Therapeutics, Inc. to be priced at 0.47 by the end of this quarter and at 0.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Baxter International 58.95 -0.76 -1.27% -20.18%
Cerus 5.09 -0.14 -2.68% -17.77%
Plus Therapeutics, Inc. 0.50 -0.02 -3.83% -73.26%
Dr.Reddys Laboratories 4,239.65 16.30 0.39% -10.65%
Genocea Biosciences 0.01 -0.0004 -3.51% -99.43%
Haemonetics 67.59 -1.06 -1.54% 17.02%
Infinity Pharmaceuticals 0.74 -0.07 -8.56% -75.17%
Merrimack Pharmaceuticals 4.16 -0.12 -2.69% -19.48%
Mirati Therapeutics 82.09 -4.61 -5.32% -43.86%
Northwest Biotherapeutics 0.65 -0.02 -2.42% -48.10%
Sanofi 95.16 -0.32 -0.34% 9.92%
Starpharma Holdings Ltd 0.76 0.02 2.03% -38.37%
Sun Pharmaceuticals 917.45 7.05 0.77% 17.69%
Teva Pharmaceutical Industries Ltd 3,660.00 -23.00 -0.62% 12.82%

Indexes Price Day Year
USND 12494 -150.53 -1.19% -15.51%
US2000 1913 -28.31 -1.46% -14.58%

Plus Therapeutics, Inc.
Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.